Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.
Senator Michael Bennet gave opening remarks at our July briefing on Breakthrough Therapy
Friends of Cancer Research's 2012 Annual Report is now available for download.
Friends Honors Governor Martin O'Malley, Governor Bob McDonnell, and philanthropist Sherry Lansing
PRT4445 (andexanet alfa) - (Portola Pharmaceuticals)
a Factor Xa inhibitor antidote
cPMP - (Alexion)
for the treatment of molybdenum cofactor deficiency (MoCD) type A
MK-5172/MK-8742 - (Merck)
for the treatment of Hepatitis C
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
"Years ago, as a young oncology nurse, I saw patients battling cancer first hand. . ."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700